Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme
The recent introduction of RZV into the NIP could substantially reduce HZ disease burden and healthcare resource use in the UK. A graphical abstract is available with this article.
Authors
- Yasmeeta Vekria
- Alen Marijam (ORCID: https://orcid.org/0000-0003-1046-9702)
- Desmond Curran (ORCID: https://orcid.org/0000-0002-7423-0111)
- Nikolaos Giannelos (ORCID: https://orcid.org/0000-0001-9130-4744)
- Manjit Hunjan (ORCID: https://orcid.org/0000-0001-8717-6153)
Institutions
- GlaxoSmithKline (Belgium) (BE)
- GlaxoSmithKline (Ireland) (IE)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1007/s40121-024-01073-3
- Citations
- 4
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.55